摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)oxy]propan-1-amine | 1391026-72-4

中文名称
——
中文别名
——
英文名称
N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)oxy]propan-1-amine
英文别名
N-[(5-chlorofuran-2-yl)methyl]-2-(1-chloronaphthalen-2-yl)oxypropan-1-amine
N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)oxy]propan-1-amine化学式
CAS
1391026-72-4
化学式
C18H17Cl2NO2
mdl
——
分子量
350.244
InChiKey
XJXXYQJEJBSVBN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    23
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    34.4
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    2-[(1-Chloronaphthalen-2-yl)oxy]propan-1-amine 、 5-氯-2-糠醛 生成 N-[(5-chlorofuran-2-yl)methyl]-2-[(1-chloronaphthalen-2-yl)oxy]propan-1-amine
    参考文献:
    名称:
    TRPM8 receptor antagonists
    摘要:
    作为瞬时受体电位阳离子通道亚家族M成员8 (以下简称TRPM8) 的选择性拮抗剂的化合物,其化学式为:其中,R选择自:H、Br、CN、NO2、SO2NH2、SO2NHR′ 和SO2NR′2,其中R′选择自线性或支链的C1-C4烷基;X选择自:F、Cl、C1-C3烷基、NH2 和OH;Y选择自:O、CH2、NH 和SO2;R1和R2,独立于彼此,选择自:H、F 和线性或支链的C1-C4烷基;R3和R4,独立于彼此,选择自:H 和线性或支链的C1-C4烷基;Z选择自:NR6 和R6R7N+,其中R6和R7独立于彼此,选择自:H 和线性或支链的C1-C4烷基;R5是选择自:H 和线性或支链的C1-C4烷基的残基;Het是选择自:取代或不取代的吡咯基、取代或不取代的N-甲基吡咯基、取代或不取代的噻吩基、取代或不取代的呋喃基和取代或不取代的吡啶基的杂环基团。所述化合物在预防和治疗依赖于TRPM8活性的病理情况,如疼痛、炎症、缺血、神经退行性疾病、中风、精神障碍、炎症性疾病和泌尿系疾病中有用。
    公开号:
    US08906946B2
点击查看最新优质反应信息

文献信息

  • [EN] TRPM8 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS TRPM8
    申请人:DOMPE SPA
    公开号:WO2012101244A1
    公开(公告)日:2012-08-02
    Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula (I), wherein R is selected from: - H, Br, CN, NO2, SO2NH2, SO2NHR' and SO2NR'2, where R' is selected from linear or branched C1-C4 alkyl; X is selected from: - F, C1, C1-C3 alkyl, NH2 and OH Y is selected from: - O, CH2, NH and SO2 R1 and R2, independently one from the other, are selected from - H, F and linear or branched C1-C4 alkyl; R3 and R4, independently one from the other, are selected from - H and linear or branched C1-C4 alkyl; Z is selected from: - NR6 and R6R7N+, where R6 and R7 independently one from the other, are selected from: • H and linear or branched C1-C4 alkyl R5 is a residue selected from: - H and linear or branched C1-C4 alkyl Het is a heteroaryl group selected from - a substituted or not substituted pyrrolyl, a substituted or not substituted N- methylpyrrolyl, a substituted or not substituted thiophenyl, a substituted or not substituted furyl and a substituted or not substituted pyridinyl. Said compounds are useful in the prevention and treatment of pathologies depending on TRPM8 activity such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.
    作为Transient Receptor Potential阳离子通道亚家族M成员8(以下简称为TRPM8)的选择性拮抗剂的化合物,具有以下式(I),其中R选自:- H、Br、CN、NO2、SO2NH2、SO2NHR'和SO2NR'2,其中R'选自线性或支链的C1-C4烷基;X选自:- F、C1、C1-C3烷基、NH2和OH;Y选自:- O、CH2、NH和SO2;R1和R2,彼此独立地选自- H、F和线性或支链的C1-C4烷基;R3和R4,彼此独立地选自- H和线性或支链的C1-C4烷基;Z选自:- NR6和R6R7N+,其中R6和R7彼此独立地选自:• H和线性或支链的C1-C4烷基;R5是从- H和线性或支链的C1-C4烷基中选出的残基;Het是从- 取代或未取代的吡咯基、取代或未取代的N-甲基吡咯基、取代或未取代的噻吩基、取代或未取代的呋喃基和取代或未取代的吡啶基中选出的杂环芳基团。所述化合物在预防和治疗依赖于TRPM8活性的病理病变中具有用途,如疼痛、炎症、缺血、神经退行性、中风、精神障碍、炎症性疾病和泌尿系统疾病。
  • TRPM8 RECEPTOR ANTAGONISTS
    申请人:Moriconi Alessio
    公开号:US20140031398A1
    公开(公告)日:2014-01-30
    Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula: Wherein R is selected from: H, Br, CN, NO 2 , SO 2 NH 2 , SO 2 NHR′ and SO 2 NR′ 2 , where R′ is selected from linear or branched C 1 -C 4 alkyl; X is selected from: F, Cl, C 1 -C 3 alkyl, NH 2 and OH Y is selected from: O, CH 2 , NH and SO 2 R1 and R2, independently one from the other, are selected from H, F and linear or branched C 1 -C 4 alkyl; R3 and R4, independently one from the other, are selected from H and linear or branched C 1 -C 4 alkyl; Z is selected from: NR6 and R6R7N + , where R6 and R7 independently one from the other, are selected from: H and linear or branched C 1 -C 4 alkyl R5 is a residue selected from: H and linear or branched C 1 -C 4 alkyl Het is a heteroaryl group selected from a substituted or not substituted pyrrolyl, a substituted or not substituted N-methylpyrrolyl, a substituted or not substituted thiophenyl, a substituted or not substituted furyl and a substituted or not substituted pyridinyl. Said compounds are useful in the prevention and treatment of pathologies depending on TRPM8 activity such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.
    具有以下式子的化合物作为瞬时受体电位阳离子通道亚家族M成员8(以下简称TRPM8)的选择性拮抗剂: 其中, R从以下选项中选择:H、Br、CN、NO2、SO2NH2、SO2NHR′和SO2NR′2,其中R′从线性或支链C1-C4烷基中选择; X从以下选项中选择:F、Cl、C1-C3烷基、NH2和OH; Y从以下选项中选择:O、CH2、NH和SO2; R1和R2各自独立地从H、F和线性或支链C1-C4烷基中选择; R3和R4各自独立地从H和线性或支链C1-C4烷基中选择; Z从以下选项中选择:NR6和R6R7N+,其中R6和R7各自独立地从H和线性或支链C1-C4烷基中选择; R5是从H和线性或支链C1-C4烷基中选择的残基; Het是从以下异芳基基团中选择的杂环基团:取代或未取代的吡咯基、取代或未取代的N-甲基吡咯基、取代或未取代的噻吩基、取代或未取代的呋喃基和取代或未取代的吡啶基。 所述化合物可用于预防和治疗依赖于TRPM8活性的病理状况,如疼痛、炎症、缺血、神经退行性疾病、中风、精神障碍、炎症性疾病和泌尿系统疾病。
  • UV-PHOTO-PROTECTING COSMETIC COMPOSITION
    申请人:Momentive Performance Materials GmbH
    公开号:EP2667947A1
    公开(公告)日:2013-12-04
  • US8906946B2
    申请人:——
    公开号:US8906946B2
    公开(公告)日:2014-12-09
  • [EN] UV-PHOTO-PROTECTING COSMETIC COMPOSITION<br/>[FR] COMPOSITION COSMÉTIQUE PHOTOPROTECTRICE CONTRE LES UV
    申请人:MOMENTIVE PERFORMANCE MAT INC
    公开号:WO2012101204A1
    公开(公告)日:2012-08-02
    The present invention related to an UV-photo-protecting cosmetic composition, comprising: (a) at least one aqueous phase, (b) at least one fatty phase, (c) at least one micronized organic UV-screening agent, the mean particle size of said micronized particles ranging from 0.01 to 2 μm, and (d) at least one organomodified silicone which does not comprise poly(oxyalkylene) moieties.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)